Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Physicians who Treat Multiple Sclerosis (EU)(?)

Council Members in this Study Group: 118

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Related Study Groups

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
April 7, 2008
LIPITOR is the most powerful statin in cardiovascular area
By a GLG Expert Contributor
Analysis of: Lipitor Provided an Unexpectedly Potent Heart Benefit in Patients with Chronic Stable Angina, According to New Study | www.pipelinereview.com

Pfizer announced today that Lipitor® (atorvastatin calcium) 80 mg showed unexpectedly potent reduction in myocardial ischemiaLipitor significantly reduced the average number of ischemic events by nearly 70 percent and total duration of events by more than 60 percent from baseline to week 18 of...

March 26, 2008
VIA 2291 reduce inflamamtion in atherosclerotic plaque , a new target in prevention
By a GLG Expert Contributor
Analysis of: VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial | www.pipelinereview.com

Plaque inflamamtion involves several process , leading to destabilisation and rupture with subsequent embolism. Antiinflammatory drugs may decrease this process, but a single target such as leucotriene decrease is not sufficient. However this trial is interesting as it provide new pathways allowing...

March 24, 2008
Glatiramer failure in ALS a multicentric andomized trial supportd by TEVA
By a GLG Expert Contributor
Analysis of: Teva Provides Update on Glatiramer Acetate 40mg for Amyotrophic Lateral Sclerosis | pharmalive.com

In amyotrophic lateral sclerosis (ALS), an involvement of the immune system in the degenerative processes has been shown in both humans and transgenic  mice Although tiramer acetate (also known as copolymer-1; COP-1; Copaxone) improves motor function and extends survival times in an inbred strain...

March 24, 2008
Neuropathic diabetic pain is increasing over the world mainly in wester countries to date many drugs allowed only a modest pain relief , this new drug has a higher potential in limiting pain and depression post-pain, the way of administration and tolerance is better that current drugs on the market , this drug may allow a de crease of depression related to pain because it may target a specific centralnervous systel receptor involving in depression process
By a GLG Expert Contributor
Analysis of: Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain | www.pipelinereview.com

Neuropathic diabetic pain is increasing over the world mainly in wester countries to date many drugs allowed only a modest pain relief , this new drug has a higher potential in limiting pain and depression post-pain, the way of administration and tolerance is better that current drugs on the market...

March 3, 2008
Payon is a firm developping antithrombotic drugs such as desmoteplase ; we used this drug in our department two clinical trials DIAS and DIAS II for treatment of acute ischemic stroke , we are aware about side effect and we are interested in new developpment in the field of antithrombotic therapy by PAYON.
By a GLG Expert Contributor
Analysis of: PAION's anticoagulant Solulin successfully tested in first-in-man study | www.pipelinereview.com

PAYON developp new antithrombotic drugs with high potential in patients with atherothrombotic stroke , these may be use at the acute phase of thrombosis and may allowed vessel recaanlization thus sparing life and decreasing morbimortality. In addition these antithrombotic drugs may prevent reccurent...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Non-Academic Community Hospital or Clinic
  • Government/Military Hospital or Clinic
  • Academic Institution*
  • Office Based Private Practice or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Division Head
  • Physician - Director
  • Physician - Department Chair
  • Physician - Fellow
  • Research Scientist
  • Professor

GLG's 850+ Clients Include:

Fortune 500®  companies
40 of the leading 50  global mutual funds
15 of the leading 20  global banks
8 of the leading 10  global private equity firms
5 of the top 10  AmLaw firms

Analytics


Generated at 2009-01-08T19:00:17.880